Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.
about
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response.Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Evaluation of tumor size response metrics to predict survival in oncology clinical trials.Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer
P2860
Simulations to Assess Phase II Noninferiority Trials of Different Doses of Capecitabine in Combination With Docetaxel for Metastatic Breast Cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Simulations to Assess Phase II ...... for Metastatic Breast Cancer.
@ast
Simulations to Assess Phase II ...... for Metastatic Breast Cancer.
@en
type
label
Simulations to Assess Phase II ...... for Metastatic Breast Cancer.
@ast
Simulations to Assess Phase II ...... for Metastatic Breast Cancer.
@en
prefLabel
Simulations to Assess Phase II ...... for Metastatic Breast Cancer.
@ast
Simulations to Assess Phase II ...... for Metastatic Breast Cancer.
@en
P2093
P2860
P356
P1476
Simulations to Assess Phase II ...... l for Metastatic Breast Cancer
@en
P2093
P2860
P356
10.1038/PSP.2012.20
P50
P577
2012-12-26T00:00:00Z